Paper Details

  1. Home
  2. Paper Details

A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9-12 month old healthy infants.

Author: GunneriSubbaReddy, MaturRamesh V, MogullaRammohan Reddy, PetaKalyankumar, SuneethaPothakamuri Venkata, ThuluvaSubhash, TuragaKishore, YerrojuVijay

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This phase-2/3 study assessed the safety and immunogenicity of Biological E's live attenuated MR vaccine (BE-MR) in 9-12 month old healthy infants. The study found that BE-MR was safe and comparable to the comparator vaccine, SII MR-Vac™. BE-MR elicited a robust and protective immune response, as demonstrated by high sero-protection rates and significant increases in anti-Measles and anti-Rubella antibodies. The study concludes that BE-MR can be safely administered to infants below one year of age.
Paper Details　
Original Abstract of the Article :
Measles is a major cause of childhood mortality and one-third of the world's Measles deaths occur in India. Rubella causes lifelong birth defects (Congenital Rubella Syndrome). Although neither condition has a cure, the MR vaccination can successfully prevent both diseases. The safety of Biological ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696430/

データ提供：米国国立医学図書館（NLM）

Safety and Immunogenicity of BE-MR Vaccine in Infants

The desert of [ワクチン] research is a vast and ever-changing landscape. This study is like a camel caravan exploring the effectiveness of [BE-MRワクチン] in [9-12ヶ月児]. The researchers are conducting a [phase II/III randomized, comparative study] to assess the safety and immunogenicity of [BE-MRワクチン] in infants. Their findings demonstrate that [BE-MRワクチン] is safe and immunogenic, providing a promising new option for protecting infants from [麻疹] and [風疹].

A Safe and Effective Solution for Infants

The researchers have found that [BE-MRワクチン] is safe and effective in protecting infants from [麻疹] and [風疹]. This discovery is like finding a new oasis in the desert, offering a safe haven for infants. This research offers hope for a future where these diseases are less prevalent, providing a healthier and more secure world for our children.

Protecting Our Youngest: The Importance of Vaccination

This study underscores the importance of vaccination in protecting our youngest population. Vaccinations are like a shield, protecting us from the harsh realities of infectious diseases. It's a reminder that by working together, we can create a healthier and safer world for everyone.

Dr.Camel's Conclusion

This study is a significant milestone in the quest to protect infants from [麻疹] and [風疹]. It's a reminder that continued research and innovation are key to improving public health and safeguarding the well-being of our future generations. This research is like a beacon of hope, guiding us toward a brighter and healthier future for all.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-12-08
Further Info :

Pubmed ID

38058513

DOI: Digital Object Identifier

PMC10696430

Related Literature

Article Analysis
・Causes of rubella
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.